The Indian companies Cipla and Serum Institute have joined hands to provide affordable pediatric vaccines in Europe.
The deal marks Cipla's broad indirect interest in vaccines play as it shores up its presence in Europe, though the...
Cipla-Serum ally for Europe vaccine push
The Indian companies Cipla and Serum Institute have joined hands to provide affordable pediatric vaccines in Europe.
More from Anti-infective
• By
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
• By
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
• By
Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.
• By
A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.
More from Therapy Areas
• By
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
• By
The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.
• By
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?